Literature DB >> 12527417

Mitochondrially mediated synergistic cell killing by bile acids.

Anabela P Rolo1, Carlos M Palmeira, Kendall B Wallace.   

Abstract

The accumulation of endogenous bile acids contributes to hepatocellular damage during cholestatic liver disease. To examine the controversy regarding the therapeutic use of ursodeoxycholate (UDCA) in cholestatic patients, we investigated the possible cytoprotection or synergistic effects of UDCA against chenodeoxycholate (CDCA)-induced injury to isolated rat hepatocytes. Our aim was to investigate the role of the mitochondrial permeability transition (MPT) in the mechanism of cytotoxicity caused by UDCA plus CDCA. Although not toxic by itself, UDCA potentiated the mitochondrial depolarization, ATP depletion and cell killing caused by CDCA. Fructose maintained ATP levels and prevented bile acid-induced cell killing. Cyclosporine A (CyA), a potent inhibitor of the MPT, substantially reduced mitochondrial depolarization, ATP depletion and cell killing caused by CDCA. Our results demonstrate that the synergistic cytotoxicity by UDCA plus CDCA is mediated by impairment of mitochondrial function, an event that is expressed via induction of the MPT.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12527417     DOI： 10.1016/s0925-4439(02)00224-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  11 in total

1.  NIM811 (N-methyl-4-isoleucine cyclosporine), a mitochondrial permeability transition inhibitor, attenuates cholestatic liver injury but not fibrosis in mice.

Authors:  Hasibur Rehman; Venkat K Ramshesh; Tom P Theruvath; Insil Kim; Robert T Currin; Shailendra Giri; John J Lemasters; Zhi Zhong
Journal:  J Pharmacol Exp Ther       Date:  2008-09-18       Impact factor: 4.030

2.  Uncovering the beginning of diabetes: the cellular redox status and oxidative stress as starting players in hyperglycemic damage.

Authors:  João Soeiro Teodoro; Ana Patrícia Gomes; Ana Teresa Varela; Filipe Valente Duarte; Anabela Pinto Rolo; Carlos Marques Palmeira
Journal:  Mol Cell Biochem       Date:  2013-01-08       Impact factor: 3.396

3.  Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis.

Authors:  Ana P Gomes; Filipe V Duarte; Patricia Nunes; Basil P Hubbard; João S Teodoro; Ana T Varela; John G Jones; David A Sinclair; Carlos M Palmeira; Anabela P Rolo
Journal:  Biochim Biophys Acta       Date:  2011-10-17

4.  SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.

Authors:  Nathan L Price; Ana P Gomes; Alvin J Y Ling; Filipe V Duarte; Alejandro Martin-Montalvo; Brian J North; Beamon Agarwal; Lan Ye; Giorgio Ramadori; Joao S Teodoro; Basil P Hubbard; Ana T Varela; James G Davis; Behzad Varamini; Angela Hafner; Ruin Moaddel; Anabela P Rolo; Roberto Coppari; Carlos M Palmeira; Rafael de Cabo; Joseph A Baur; David A Sinclair
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

5.  Apoptosis-inducing factor plays a role in the pathogenesis of hepatic and renal injury during cholestasis.

Authors:  Vahid Ghanbarinejad; Akram Jamshidzadeh; Bahman Khalvati; Omid Farshad; Huifeng Li; Xiong Shi; Yuanyu Chen; Mohammad Mehdi Ommati; Reza Heidari
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-02-01       Impact factor: 3.000

6.  SRT1720 improves survival and healthspan of obese mice.

Authors:  Robin K Minor; Joseph A Baur; Ana P Gomes; Theresa M Ward; Anna Csiszar; Evi M Mercken; Kotb Abdelmohsen; Yu-Kyong Shin; Carles Canto; Morten Scheibye-Knudsen; Melissa Krawczyk; Pablo M Irusta; Alejandro Martín-Montalvo; Basil P Hubbard; Yongqing Zhang; Elin Lehrmann; Alexa A White; Nathan L Price; William R Swindell; Kevin J Pearson; Kevin G Becker; Vilhelm A Bohr; Myriam Gorospe; Josephine M Egan; Mark I Talan; Johan Auwerx; Christoph H Westphal; James L Ellis; Zoltan Ungvari; George P Vlasuk; Peter J Elliott; David A Sinclair; Rafael de Cabo
Journal:  Sci Rep       Date:  2011-08-18       Impact factor: 4.379

7.  Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome.

Authors:  Siamak MahmoudianDehkordi; Matthias Arnold; Kwangsik Nho; Shahzad Ahmad; Wei Jia; Guoxiang Xie; Gregory Louie; Alexandra Kueider-Paisley; M Arthur Moseley; J Will Thompson; Lisa St John Williams; Jessica D Tenenbaum; Colette Blach; Rebecca Baillie; Xianlin Han; Sudeepa Bhattacharyya; Jon B Toledo; Simon Schafferer; Sebastian Klein; Therese Koal; Shannon L Risacher; Mitchel Allan Kling; Alison Motsinger-Reif; Daniel M Rotroff; John Jack; Thomas Hankemeier; David A Bennett; Philip L De Jager; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; P Murali Doraiswamy; Cornelia M van Duijn; Andrew J Saykin; Gabi Kastenmüller; Rima Kaddurah-Daouk
Journal:  Alzheimers Dement       Date:  2018-10-15       Impact factor: 16.655

8.  Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.

Authors:  Kwangsik Nho; Alexandra Kueider-Paisley; Siamak MahmoudianDehkordi; Matthias Arnold; Shannon L Risacher; Gregory Louie; Colette Blach; Rebecca Baillie; Xianlin Han; Gabi Kastenmüller; Wei Jia; Guoxiang Xie; Shahzad Ahmad; Thomas Hankemeier; Cornelia M van Duijn; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; P Murali Doraiswamy; Andrew J Saykin; Rima Kaddurah-Daouk
Journal:  Alzheimers Dement       Date:  2018-10-15       Impact factor: 16.655

9.  Role of glucuronidation for hepatic detoxification and urinary elimination of toxic bile acids during biliary obstruction.

Authors:  Martin Perreault; Andrzej Białek; Jocelyn Trottier; Mélanie Verreault; Patrick Caron; Piotr Milkiewicz; Olivier Barbier
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Serum Metabonomics Analysis of Liver Failure Treated by Nonbioartificial Liver Support Systems.

Authors:  Chunyan Wu; Ying Zhu; Mengqian Yu
Journal:  Can J Gastroenterol Hepatol       Date:  2018-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.